Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
705
Views
22
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk

Koen Van BesienDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;Correspondence[email protected]
,
Lizamarie Bachier-RodriguezDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Michael SatlinTransplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, NY, USA;
,
Maxwell A. BrownDepartment of Pharmacy, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA;
,
Usama GergisDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Danielle GuarneriDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Jingmei HsuDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Adrienne A. PhillipsDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Sebastian A. MayerDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Amrita D. SinghDepartment of Pharmacy, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA;
,
Rosemary SoaveTransplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, NY, USA;
,
Adriana RossiDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
,
Catherine B. SmallTransplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, NY, USA;
,
Thomas J. WalshTransplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, NY, USA;
,
Hanna RennertDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
&
Tsiporah B. ShoreDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA;
 show all
Pages 1693-1696 | Received 25 Jul 2018, Accepted 29 Oct 2018, Published online: 10 Feb 2019

References

  • van Besien K, Liu H, Jain N, et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19:682–691.
  • Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438–6445.
  • van Besien K, Childs R. Haploidentical cord transplantation, the best of both worlds. Semin Hematol. 2016;53:257–266.
  • Bachier Rodriguez L, Shore TB, Gergis U, et al. Novel risk factors for Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorder (PTLD) after allogeneic hematopoietic stem cell transplant. Blood. 2017;130:1949.
  • Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002–4008.
  • Burns DM, Rana S, Martin E, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 2016;51:825–832.
  • Savani BN, Pohlmann PR, Jagasia M, et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood. 2009;113:6263–6264.
  • Choe HK, Gergis U, Mayer SA, et al. The addition of low-dose total body irradiation to fludarabine and melphalan conditioning in haplocord transplantation for high-risk hematological malignancies. Transplantation. 2017;101:e34–ee8.
  • Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37:307–310.
  • Abeynayake J, Johnson R, Libiran P, et al. Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods. J Clin Microbiol. 2014;52:3802–3804.
  • Klein JP, Rizzo JD, Zhang MJ, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909–915.
  • Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.
  • Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:921–923.
  • Ha VH, Ghosh S, Leyshon C, et al. Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. J Oncol Pharm Pract. 2018;24:323–331.
  • Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–3671.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.